510(k) device
Msc Sfm
Yocon Biology Technology Company · Media, Culture, Ex Vivo, Tissue And Cell (NDS, Class II) · First FDA decision Sep 6, 2024, newest Sep 6, 2024Infertility
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Msc Sfm"
MAUDE reports
0
Brand "Msc Sfm", since 2015
PubMed studies
12
Mentioning "Msc Sfm"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Msc Sfm
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- MSC SFM510(k)
K232543 · Decided Sep 6, 2024 · 381 days after receipt
Device type: Media, Culture, Ex Vivo, Tissue And Cell (NDS) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Msc Sfm", any status and sponsor, newest update first.
No registered device study names "Msc Sfm".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Msc Sfm", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NDS
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Msc Sfm"[tiab]. The summary above synthesizes these.
- Umbilical cord-derived mesenchymal stem cells cultured in the MCL medium for aplastic anemia therapy.
He C, Yang C, Zeng Q, et al. · Stem Cell Res Ther · 2023Research Support, Non-U.S. Gov't
- Comparative Analysis of Serum and Serum-Free Medium Cultured Mesenchymal Stromal Cells for Cartilage Repair.
Kang M, Yang Y, Zhang H, et al. · Int J Mol Sci · 2024Comparative Study
- Feasibility and efficacy of bone tissue engineering using human bone marrow stromal cells cultivated in serum-free conditions.
Agata H, Watanabe N, Ishii Y, et al. · Biochem Biophys Res Commun · 2009Research Support, Non-U.S. Gov't
- Effects of Oral Cavity Stem Cell Sources and Serum-Free Cell Culture on Hydrogel Encapsulation of Mesenchymal Stem Cells for Bone Regeneration: An In Vitro Investigation.
Arpornmaeklong P, Boonyuen S, Apinyauppatham K, et al. · Bioengineering (Basel) · 2024
- Conditioned serum-free medium from umbilical cord mesenchymal stem cells has anti-photoaging properties.
Liu Q, Luo Z, He S, et al. · Biotechnol Lett · 2013Research Support, Non-U.S. Gov't
- Mass spectrometry analysis of adipose-derived stem cells reveals a significant effect of hypoxia on pathways regulating extracellular matrix.
Riis S, Stensballe A, Emmersen J, et al. · Stem Cell Res Ther · 2016Research Support, Non-U.S. Gov't
- Isolation and prolonged expansion of oral mesenchymal stem cells under clinical-grade, GMP-compliant conditions differentially affects "stemness" properties.
Bakopoulou A, Apatzidou D, Aggelidou E, et al. · Stem Cell Res Ther · 2017
- Characterization of Human Fetal Cartilage Progenitor Cells During Long-Term Expansion in a Xeno-Free Medium.
Kim HR, Kim J, Park SR, et al. · Tissue Eng Regen Med · 2018
- Evaluation of GMP-compliant culture media for in vitro expansion of human bone marrow mesenchymal stromal cells.
Wuchter P, Vetter M, Saffrich R, et al. · Exp Hematol · 2016
- Development of fully defined xeno-free culture system for the preparation and propagation of cell therapy-compliant human adipose stem cells.
Patrikoski M, Juntunen M, Boucher S, et al. · Stem Cell Res Ther · 2013Research Support, Non-U.S. Gov't
- Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro.
Lindroos B, Boucher S, Chase L, et al. · Cytotherapy · 2009Comparative Study, Research Support, Non-U.S. Gov't
- [Pooled Umbilical Cord Blood Plasma for Culturing UCMSC and Ex Vivo Expanding Umbilical Cord Blood CD34⁺ Cells].
Wu JY, Lu Y, Chen JS, et al. · Zhongguo Shi Yan Xue Ye Xue Za Zhi · 2015
Other devices of this type
Also filed under product code NDS.
- MoFi Cell Culture Basal MediumDuogenic Stemcells Corporation · 510(k) 2024
- PRIME-XV FreezIS DMSO-Free MDFujifilm Irvine Scientific · 510(k) 2023
- Ct-StorEnergy Delivery Solutions · 510(k) 2021
- Optmizer Cts T-Cell Expansion Serum Free MediumLife Technologies, Inc. · 510(k) 2012
- Stempro Msc SfmLife Technologies Corporation · 510(k) 2011
- Knockout Sr Medium, Knockout Sr Xenofree Medium Model 10828, 12618Life Technologies Corporation · 510(k) 2010
- Aim-V (R) Medium, Model 087-0112Invitrogen Corporation · 510(k) 2002
- Dulbecco's Modified Eagle Medium (Dmem)Life Technologies, Inc. · De Novo 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.